Signal Genetics, a Carlsbad, California- based commercial-stage molecular diagnostic company, and Miragen Therapeutics, a Boulder, Colorado-based privately-held biopharmaceutical company have entered into a definitive merger agreement under which the stockholders of miRagen are to become holders of approximately 96% of Signal's outstanding common stock. The proposed merger remains subject to certain conditions, including approval by Signal's and miRagen's stockholders. In conjunction with the proposed merger, an investor syndicate comprised of existing miRagen investors and new investors has committed to invest approximately $40 million in miRagen immediately prior to the closing of the proposed merger.